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Abstract
The objective of this paper is to address the dramatic impact of multislice CT (MSCT) in imaging the liver. Standard
helical (spiral) CT has finally allowed for scanning the majority of the liver during the critical portal venous phase
(PVP). This is often referred to as the ‘optimal temporal window’. In general, it occurs following a 70 s scan delay
and is coincidental with the maximal delivery of contrast via the portal vein that provides 80% of the hepatic blood
supply. This yields maximal conspicuity between low-attenuation lesions and the dramatically enhanced normal liver
parenchyma at routine injection rates of 2–3 ml/s. Most importantly, these scanners, when compared to single-slice
scanners, avoid impinging on the ‘equilibrium’ phase where tumors can become isodense/invisible. The introduction
of MSCT with four, eight and 16-detector systems has significantly increased imaging speed. Volumetric CT will
continue to increase speed in the future. This provides a number of important gains that will be described.
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Introduction
The development of multislice CT (MSCT) technology
represents a substantial technological advance in CT.
The dramatic four- to eight-fold increase in imaging
speed accomplishes several things. It (a) makes the
examination more comfortable, (b) provides a higher
quality examination, (c) provides more flexibility for
scanning with thinner sections and (d) gives increased
flexibility in scanning during multiple phases of hepatic
enhancement; this includes the hepatic arterial phase
(HAP), the PVP, retrospective reconstruction of thinning
sections, and now the ability to perform exquisite 3D
vascular imaging.
When conventional helical CT is used there is
continuous data acquisition. This is related to the intrinsic
technology of the scanner that consists of a detector made
up of an array of rectangular channels. The collimation
generally ranges from 1 to 10 mm slice thickness for
these scanners. With the evolution to MSCT scanners,
manufacturers have developed different arrays which,
instead of being long and rectangular, are divided into
matrices that generally fall into two different categories:
one group has detector elements of equal width along
the z-axis (matrix detectors) and the other group has
detector elements of unequal width (adaptive array
detectors). These scanners tend to be very fast (sub-
second).
There are specific clinical advantages in assessing
both primary and metastatic liver disease using MSCT.
Two clinical applications are directly obvious. Firstly,
increased coverage using the same thickness as with
earlier scanners; secondly, the generation of much thinner
sections with similar anatomical coverage. Hybrid
approaches yield a combination of thinner sections and
greater anatomic coverage.
The options and methods of scanning the liver are
numerous, with no single approach being definitive;
different approaches are often appropriate when specific
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disease entities are suspected. The two major phases
of a liver study are the HAP and the PVP. Scans can
also be performed pre-contrast and in the equilibrium
phase (limited value, i.e. cholangiocarcinoma). For most
protocols, a scan delay of 60–70 s after initiating contrast
injection is appropriate, with newer scanners using con-
ventional rates of contrast injection (2–4 ml/s). At faster
rates, earlier scanning may be desired. One option is to
use computer-assisted scanning technology (CAST) and
begin scanning at a 50 HU threshold to optimise hitting
the peak liver enhancement (SmartPrep R© , GE, General
Electric Medical Systems, Milwaukee, WI) and assure
scanning at the optimal PVP.
In some cases, adequate hepatic enhancement has been
reported with iodine doses that are 25% lower than
conventional CT. This is especially important in certain
economic climates. If a patient’s weight is taken into
account, an even more pronounced reduction in contrast


















Figure 1 Distribution of delay times for different
patients because of different circulation times.
Most pathology in metastatic disease is hypovascular.
MSCT allows one to capture the peak of the portal
venous phase (PVP) because of its short scan time
relative to standard helical CT (Figs 5 and 6). When
confronted with hypervascular lesions that are most
commonly from metastatic islet cell tumors, melanoma,
choriocarcinoma, renal cell carcinoma, thyroid carci-
noma and, in some cases, breast carcinoma, a dual-
phase study is recommended (Figs 7–9). The addition
of the HAP component initiated at 15–20 s into the
study can increase lesion detection by 8–13% compared
to PVP imaging alone. Scans at 5 or 7.5 mm have
become standard. Thinner collimations can detect more
lesions, but these often remain indeterminate because
of their extremely small size. In one series where
images of the liver were reconstructed with overlapping
collimation, 7% more lesions could be detected. An
early arterial phase (AP) has the additional value of
producing superb 3D imaging of the vascular system
depicting hepatic arterial anatomy preoperatively. It is
also of value in assessing patients who are candidates for
intra-arterial chemotherapy. This flexibility of multislice
scanning generally avoids more invasive techniques i.e.
angiographic CT arterial portography (CTAP).
In cases where a CT angiogram (CTA) is desired, a
triple rather than dual-phase study may be substituted.
The true AP is performed 10 s after contrast initiation
followed by the late arterial phase (LAP) and PVP phases.
(HAP = 25 s, PVP = 65–70 s) after initiating the
contrast bolus. Collimation of 5–7 mm and injection
rates of 4–6 ml/s are used. The time saving is clearly
evident with the use of multislice as seen in Fig. 5 by
the decreased scanning time.
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Figure 2 Distribution of fixed delay time vs. CAST.
This shows that when a bolus tracking program such
as a computer automated scan time (CAST) is used,
patients’ scans have better contrast enhancement in
the liver than with a fixed delay.
In imaging the liver, disease entities may be divided
into focal (metastases, focal fat) or diffuse (fatty infiltra-
tion, cirrhosis and hemachromatosis). Focal lesions can
be either primary or metastatic in origin (Figs 7–9).
Primary lesions
Primary lesions consist of both benign and malignant
lesions.
Hepatic hemangioma
Hepatic hemangioma is the most common benign tumor
occurring more commonly in women and with multiplic-
ity up to 10%. Often less than 3 cm, they can attain a con-
siderable size. They have a typical imaging appearance on
non-contrast scans of a low-attenuation mass with areas
measuring blood density. On post-contrast enhancement
there is peripheral clumping of enhancement that
proceeds from the periphery towards the center of the
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Figure 3 (a) Benefits of an individualized delay approach to liver scanning. (b) Computer automated scan
technology or bolus tracking benefits.





























Figure 5 (a) Hypovascular metastases time–density curve with single slice CT. (b) Hypovascular metastases
time–density curve with multislice, multidetector CT.
152 P M Silverman
lesion. Complete fill-in is not required for accurate
diagnosis since many may have fibrosis or thrombosis.
Spontaneous hemorrhage is rare. Histologically they rep-
resent thin-wall endothelialline spaces fed by peripheral
hepatic arterial branches. When there is a question as to
diagnosis, a nuclear medicine RBC SPECT scan or MR
can usually be definitive.
Liver Contrast Dynamics
Figure 6 Hypovascular metastases. L-R: Non-
contrast shows liver metastasis in right lobe. Follow-
ing contrast, lesion is better seen during PVP. Image
on right shows lesion disappearing shortly after PVP.
Figure 7 Hypervascular metastasis. Using single
slice helical CT, the early hepatic arterial dominant
phase (HADP) shows the lesions well but they are less
well seen during PVP in the image on the right.
Figure 8 Tri-phasic study, hypervascular metas-
tasis. Hepatic arterial phase (HAP) on left shows
early enhancement of tumors. The late arterial phase
(LAP), center, shows lesions but the PVP on the right
is inadequate.
Figure 9 Hypervascular metastasis. Hepatic arte-
rial phase (HAP) on the left shows lesions optimally.
Center image during later arterial phase (LAP)
shows lesions poorly. Portal venous phase (PVP) is
suboptimal for hypervascular tumor.
Focal nodular hyperplasia (FNH)
FNH is the second most common benign hepatic tumor.
These are multiple in up to 20% of cases, most common
in women and generally asymptomatic. CT demonstrates
these lesions to be homogeneously hyperdense during the
AP and isodense during the PVP phase. Approximately
half of the lesion’s hepatocytes demonstrate a central low
hypoattenuating scar. The lesions consist of hepatocytes,
bile ducts, and Kupffer cells. They are thought to be the
result of congenital vascular malfunctions which induced
localised hyperplasia.
Hepatocellular adenoma (HCA)
HCA is a benign vascular neoplasm primarily occurring
in young women with a strong association with oral
contraceptive use. These tumors do have malignant
potential and a tendency to undergo spontaneous hemor-
rhage. The CT appearance is of a slightly heterogeneous
area of increased enhancement during the HAP, which
becomes isodense during the PVP. Lesions may contain
fat or have hemorrhage and be difficult to distinguish
from hepatocellular carcinoma (HCC). They lack bile
duct epithelium. MR imaging characteristics include
hypointense to hyperintense on T1-weighted sequences
depending on the presence of hemorrhage, which creates
a mixed appearance. T2-weighted sequences are iso- to
hyperintense and often heterogeneous. Surgical resection
eliminates the possibility of spontaneous potentially life-
threatening hemorrhage or the development of HCC.
HCC
HCC is the most common primary hepatic malignancy
worldwide with approximately 70–80% having under-
lining cirrhosis (Fig. 10). It is especially common in
Asia and Northern Africa, where there is an increased
incidence of patients with hepatitis B and C. It is an
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Figure 10 Staging system for hepatocellular carcinoma.
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aggressive, vascular lesion, best appreciated in the late
HAP portion of the CT. Small lesions may have a homo-
geneous enhancement which become heterogeneous as
the lesions enlarge. These lesions have a tendency to
invade portal and even hepatic veins and may have small
amounts of fat. The staging of HCC is shown. The
fibrolamellar HCC lesion is a less virulent variety that has
a central scar.
Cholangiocarcinoma
Cholangiocarcinoma is a less common lesion of bile
duct origin and is not common extrahepatically; it
includes the porta hepatis, termed Klatskin tumors
and less commonly seen as intrahepatic lesions. It
tends to have lower attenuation on the HAP and PVP
phases, but frequently delayed images (10–15 min) show
a characteristically dense enhancement, unlike HCC
central calcifications that are often seen (40%).
Epithelioid hemangioendothelioma (EHG)
EHG are malignant lesions in which calcifications may be
observed. They are often seen better on unenhanced CT
scans and demonstrate moderate contrast enhancement,
but incomplete filling of the lesion on non-delayed
images. When large, they may be associated with an
abnormal hepatic contour related to capsular retraction
and hypertrophy. They generally have a slow growth
rate and compensatory hypertrophy may be seen in the
unaffected liver. Histologically, these tumors have large
areas of desmoplasia and fibrosis, accounting for the
biliary ductal dilatation often seen peripheral to the
tumor. When encasement of the portal venous system
occurs, the result is lobar atrophy.
Secondary disease
Secondary disease (metastatic disease to the liver)
overwhelmingly appears as low-density lesions in the
liver during the PVP phase. Thus the HAP is not
necessary. There may be an element of some peripheral
enhancement to these lesions which is often irregular.
Lesions are often multiple and may occur from a wide
variety of sites although gastrointestinal primaries are one
common etiology.
The select group of hypervascular lesions (e.g.
melanoma, islet cell tumors, carcinoid, renal, thyroid,
choriocarcinoma and in some cases breast carcinoma)
require the minimum of a dual-phase study where
multislice imaging is extremely effective. Triple-phase
studies are valuable to provide an early AP for 3D image
processing [10].
Conclusion
The introduction of multislice CT has from the beginning
revolutionized the approach to imaging the liver, provid-
ing increased flexibility to improve diagnostic imaging.
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